ctDNA-guided therapy for advanced stomach cancer after neoadjuvant treatment
Part of Cancer clinical trials.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 79 years old.
- You have been diagnosed with advanced stomach or gastroesophageal junction cancer (stages cIII to cIVa) that can be surgically removed.
- You are in reasonably good health (ECOG score 0–2) and can tolerate surgery.
- You have adequate blood cell counts and organ function (kidney, liver, blood clotting).
- You have not yet started any treatment for this cancer before entering the trial.
- If you could become pregnant, you agree to use contraception during the study and for 24 months after the last dose of medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a blood test for cancer DNA (ctDNA) can help decide if more chemotherapy is needed after surgery and chemo for advanced stomach cancer. It may help tailor treatment to your individual risk of cancer returning.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.